The launch, into the second-largest European aesthetic toxin market, represents a significant step in the company’s geographic expansion.
The performance beauty company Evolus, Inc. has commenced the commercial launch of Nuceiva® (botulinum toxin type A) in Germany and Austria. It is now available for direct order and delivery to customers in the two countries.
Evolus is partnering with Novvia, a leading supplier of specialist products to aesthetics practitioners, to commercialise the product in Germany and Austria.
Nuceiva® is currently commercially available in Canada and Great Britain– the largest aesthetic market in Europe.¹ The product is also approved for sale in the US under the brand name Jeuveau®.
The launch into Germany and Austria signals a significant step in Evolus, Inc.’s aims for geographic expansion. The company expects to enter additional European countries as well as Australia in 2023.
“We are excited to introduce Nuceiva ® to customers in Germany and Austria, the second largest aesthetic toxin market in Europe,¹ ” said the president and chief executive of Evolus Inc., David Moatazedi. “Entering this dynamic European market is the latest in a series of geographical expansion milestones that will help fuel Evolus’ above-market average growth in the underpenetrated aesthetic neurotoxin market.”
“We understand the importance of choice – not just to patients, but also to our customers, and we’re thrilled to bring a new neurotoxin to Germany and Austria,” continued the vice president and general manager of Evolus International, Dan Stewart. “Along with our distributor partner Novvia, we are offering educational programs to aesthetic doctors so they can learn more about how to use this specific product and evolve their practice.”
“With the availability of Nuceiva® in Germany, I will now have more choice,” revealed the international aesthetic expert and dermatologist Dr Thomas Zimmermann. “My practice has the opportunity to deliver more of what my patients want – precision-driven results using innovative products supported by robust clinical data. This product, along with the company’s medical education and training programs and modern manufacturing standards, will be instrumental in evolving my practice and ultimately meeting the needs of my patients.”
Nuceiva® is approved by the European Commission for the temporary improvement of the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity has an important psychological impact in adults below 65 years of age.²
The safety and efficacy of Nuceiva® was evaluated through the company’s TRANSPARENCY clinical program – which included the largest head-to-head aesthetic pivotal study versus Botox® (onabotulinumtoxinA) to date. For more information, visit evolus.com.
References:
1. Data on file: Decision Research Group (DRG) Aesthetic Injectables Market Insights, Europe, 2021.
2. https://www.ema.europa.eu/en/documents/product-information/nuceiva-epar-product-
information_en.pdf
